Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Alder BioPharmaceuticals Inc. said its injection to prevent migraines had met the main goal in a mid-stage study.
There’s a slightly hollow feeling about the faded business park which was once home to Pfizer’s bustling R&D community and supported thousands of jobs in the nearby town of Sandwich.
While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs.
The analysts at Thomson Reuters have consulted their crystal balls and come up with seven drugs coming out this year that will likely hit blockbuster status – defined as marking more than $1 billion annually.
March 25, 2016 By Mark Terry, BioSpace.com Breaking News Staff Waltham, Mass.-based FORUM Pharmaceuticals, in light of two Phase III trial disappointments, is laying off half its staff and restructuring the company. In September 2015, the U.S. Food and Drug Administration (FDA) advised FORUM to halt its clinical trials of encenicline for Alzheimer’s disease. […]
Patients who have a heart rhythm disorder that can come with a high risk of stroke often don’t receive blood-thinning medications that can make this complication less likely, a U.S. study suggests. Researchers studied almost 430,000 people with a condition known as atrial fibrillation, an irregular rapid heartbeat that can lead to stoke, heart failure […]
Portola Pharmaceuticals Inc said data showed its oral anticoagulant missed the main goal of preventing blood clots in acutely ill patients in a late-stage study. The company’s shares fell 30 percent to a two-year low of $20.00 in early trading. Portola’s betrixaban, designed for the prevention of venous thromboembolism (VTE), or blood clots, was tested […]
TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating the combination therapy as a co-formulated […]
AstraZeneca’s heart drug Brilinta has failed to help stroke patients as hoped in a big clinical trial, dealing a blow to the company’s expectations that the medicine could rack up annual sales of $3.5 billion by 2023. The trial found the blood-thinner was not significantly better than aspirin, the current standard of care, in […]
French drugmaker Sanofi and U.S. partner Regeneron said a late-stage study of their Praluent injection showed it reduced the need for patients with an inherited form of high cholesterol to have bad cholesterol removed from their blood. “This is the first time a PCSK9 inhibitor has shown in a clinical study that it reduced […]
Fitness trackers may be a trendy way to monitor every step we take, but these gadgets are actually pretty bad at keeping tabs on how much energy we burn, a new study suggests.
BioMarin’s genetic disorder drug met the study’s main goal of reducing a toxic buildup of an amino acid, but did not show enough benefit in related inattention and mood complications.
Johnson & Johnson’s Stelara psoriasis drug has shown effectiveness against Crohn’s disease in a second late-stage trial, bolstering prospects of its approval for the additional use.
Thousands of pregnant women caught in the outbreak of the mosquito-borne virus spreading from Brazil risk having a baby with the birth defect microcephaly, according to study results.
Gilead Sciences halted six trials for its cancer drug Zydelig following concerns of adverse effects and deaths.
Researchers should be more cautious in dosing experimental medicines in early human trials, even when drugs are thought to be low risk, experts reviewing a French clinical study that left one person dead said on Wednesday. The volunteer died and five others became seriously ill in January after being given high doses of a […]
For people with Alzheimer’s disease, having gum disease is tied to faster cognitive decline, according to a new study. “What we have shown is that regardless of the severity of dementia (within this mild to moderate impaired group) that patients with more severe gum disease are declining more rapidly,” said senior author Clive Holmes of […]
A new book by bestselling author John Grisham is giving new impetus to a handful of companies striving to develop what could be a trailblazing treatment for cancer and AD.
A top NFL official acknowledged for the first time on Monday a link between football-related concussions and chronic traumatic encephalopathy (CTE).